Achieve Life Sciences, Inc. (QUIT)
NASDAQ: QUIT · Real-Time Price · USD
6.29
-0.16 (-2.48%)
At close: Nov 12, 2026, 4:00 PM EST
6.29
0.00 (0.00%)
After-hours: Nov 12, 2026, 4:15 PM EST
Company Description
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothell, Washington.
Achieve Life Sciences, Inc.
| Country | United States |
| Employees | 28 |
| CEO | Andrew Goldberg |
Contact Details
Address: 22722 29th Dr. SE, Suite 100 Bothell, Washington 98021 United States | |
| Phone | 604 210 2217 |
| Website | achievelifesciences.com |
Stock Details
| Ticker Symbol | QUIT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000949858 |
Key Executives
| Name | Position |
|---|---|
| Andrew Goldberg | Chief Executive Officer |
| Benjamin Halladay | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 10, 2026 | 10-Q | Quarterly Report |
| Nov 10, 2026 | 8-K | Current Report |
| Oct 1, 2026 | 8-K | Current Report |
| Aug 19, 2026 | 144 | Filing |
| Aug 17, 2026 | SCHEDULE 13G | Filing |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 424B5 | Filing |
| Aug 13, 2026 | SCHEDULE 13G | Filing |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |